Bacil Pharma (524516) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
14 Oct, 2026Executive summary
Q2 FY26/27 revenue was ₹9.18 lakh; H1 revenue was ₹18.09 lakh versus ₹105.74 lakh in H1 FY25/26.
H1 standalone profit after tax was a loss of ₹2.59 lakh; consolidated loss after tax was ₹8.83 lakh.
Financial highlights
Q2 consolidated PBT was a loss of ₹2.99 lakh and H1 consolidated PBT was ₹3.65 lakh; comparative H1 FY25/26 PBT was ₹91.20 lakh.
H1 OCI gain on fair valuation of financial assets was ₹48.01 lakh; consolidated total comprehensive income was ₹39.18 lakh.
Standalone H1 total comprehensive income was ₹45.42 lakh, including ₹48.01 lakh of OCI fair-valuation gains.
Segment performance
One reportable primary pharmaceutical business segment under Ind AS 108.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bacil Pharma
- Quarterly profit after tax reached ₹30.12 lakhs on flat revenue of ₹8.91 lakhs.524516
Q1 26/27 - FY26 saw higher revenue but a net loss due to investment valuation, with operations yet to restart.524516Q4 25/26
- Quarterly net profit rose to ₹3.92 lakhs with improved revenue and clean auditor review.524516Q3 25/26
- Sharp drop in revenue and profit, with auditors issuing a disclaimer due to major uncertainties.524516Q2 25/26
- Profit rebounded sharply in Q1 FY26, but auditor raised concerns over fund application.524516Q1 25/26
- Q2 FY25 saw a sharp turnaround to profit and revenue growth, but loan recoverability remains uncertain.524516Q2 24/25
- Quarterly loss before tax, but profit after OCI; auditor flags loan recoverability concerns.524516Q1 24/25
- FY25 saw significant revenue and profit growth, but loan recoverability remains a concern.524516Q4 24/25
- Net loss in Q3 FY25, no core revenue, and auditor flags loan recoverability concerns.524516Q3 24/25